What is Leap Therapeutics Profitability Rank?
Leap Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Leap Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, Leap Therapeutics's Piotroski F-Score is 2.
Competitive Comparison of Leap Therapeutics's Profitability Rank
For the Biotechnology subindustry, Leap Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leap Therapeutics's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Leap Therapeutics's Profitability Rank falls into.
Leap Therapeutics Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Leap Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Leap Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Leap Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Leap Therapeutics (Leap Therapeutics) Business Description
Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Executives
| Jason Baum |
officer: Chief Scientific Officer |
LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
| Patricia A. Martin |
director |
316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260 |
| Christian M Richard |
director |
100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110 |
| Richard Schilsky |
director |
LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141 |
| Beigene, Ltd. |
10 percent owner |
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
| Christine Granfield |
officer: VP, Head of Reg Affairs/Qual |
C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| John Mark O'mahony |
officer: Chief Manufacturing Officer |
C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
| Cynthia Sirard |
officer: Chief Medical Officer |
C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Perceptive Advisors Llc |
10 percent owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Christopher Mirabelli |
director, 10 percent owner, officer: CEO,Pres,Chairman of the Board |
55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
| Augustine Lawlor |
10 percent owner, officer: Chief Operating Officer |
55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142 |
| Douglas E Onsi |
10 percent owner, officer: CFO,Gen Counsel,Treas, Sec. |
C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Healthcare Ventures Ix, L.p. |
10 percent owner |
55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LPTX has been successfully added to your